Andy Chen
Stock Analyst at Wolfe Research
(0)
# 4490
Out of 5,243 analysts
30
Total ratings
27.78%
Success rate
-13.60%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Immunovant | Downgrades: Peer Perform | n/a | n/a | n/a | 2 | Jan 3, 2025 | |
argenx | Upgrades: Outperform | 697 | 661.79 | 5.32% | 2 | Nov 12, 2024 | |
Alnylam Pharmaceutic... | Downgrades: Underperform | n/a | n/a | n/a | 2 | Nov 12, 2024 | |
Incyte | Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Oct 1, 2024 | |
Celldex Therapeutics | Downgrades: Peer Perform | n/a | n/a | n/a | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Peer Perform | n/a | n/a | n/a | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | 65 | 41.99 | 54.8% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Peer Perform | n/a | n/a | n/a | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Peer Perform | n/a | n/a | n/a | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 1 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Peer Perform | n/a | n/a | n/a | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 17 | 11.09 | 53.29% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Peer Perform | n/a | n/a | n/a | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | n/a | n/a | n/a | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 42 | 69.39 | -39.47% | 1 | Feb 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 60 | 1.08 | 5455.56% | 1 | Aug 8, 2023 |